The current financial score of GT Biopharma Inc is 7.52. Its financial status is robust, and its operating efficiency is low.
The current valuation score of GT Biopharma Inc is 7.79. Its current P/E ratio is -0.62, which is -98.35% below the recent high of -0.01 and -212.66% above the recent low of -1.93.
The current earnings forecast score of GT Biopharma Inc is 8.00. The average price target is 75.00, with a high of 75.00 and a low of 75.00.
The current price momentum score of GT Biopharma Inc is 6.01. Currently, the stock price is trading between the resistance level at 6.25 and the support level at 2.42, making it suitable for range-bound swing trading.
The current institutional shareholding score of GT Biopharma Inc is 3.00. The latest institutional shareholding proportion is 6.79%, representing a quarter-over-quarter increase of 106.12%.
The current risk assessment score of GT Biopharma Inc is 1.90. The company's beta value is 1.17. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.